Medication Guides
Confirmed accurate: August 6, 2026

Farxiga Savings Card 2026: $0–$150 Guide, AZ&Me Update, and the New Generic

~$650/mo brand, cash List Price
$0–$500/mo, depends on coverage With Savings Card
Often <$150/mo generic + coupon Generic Dapagliflozin
Evan Brown
Written by Evan Brown
Prescription Savings Researcher
Dr Megan Harris Medically Reviewed by Dr. Megan Harris, MD
Why trust this guide: We pulled current terms directly from AstraZeneca's own Farxiga savings page, cross-checked the AZ&Me program's official update notice, and confirmed the FDA's April 2026 generic dapagliflozin approval. Program terms are set by AstraZeneca and the FDA and can change — always confirm current details at enrollment.
Quick Answer

The Farxiga Savings Card is AstraZeneca's manufacturer copay program for brand-name Farxiga (dapagliflozin). Commercially insured patients can pay as little as $0 for a 30-day supply, capped at $175 in savings per fill. Cash-paying, uninsured patients don't get a flat low price — AstraZeneca contributes up to the first $150 toward whatever the pharmacy charges, and you owe the rest, which is often still several hundred dollars. Medicare and Medicaid patients aren't eligible for this card at all.

Two things changed the picture in 2026: the FDA approved the first generic dapagliflozin in April, and AstraZeneca is now phasing Farxiga out of its AZ&Me free patient assistance program as a direct result. For a lot of patients, especially the uninsured, the generic plus a free discount coupon now beats what's left over after the brand card's cash-pay contribution.

Key Takeaways

  • Commercially insured: $0 per 30-day supply, up to $175 in savings — usually the best option if you qualify.
  • Uninsured/cash-pay: AstraZeneca covers up to $150 of the price; you're still responsible for the rest, which can be several hundred dollars for brand-name Farxiga.
  • Not eligible for the card: Medicare, Medicaid, or any other government-funded prescription plan.
  • AZ&Me stopped taking new Farxiga/Xigduo XR applicants on May 1, 2026 and fully removes the drugs from the program on December 31, 2026, because generics now exist.
  • Generic dapagliflozin launched in April 2026 from more than a dozen manufacturers, and combined with a free coupon it can beat the brand card's leftover cash-pay balance.

Farxiga (dapagliflozin) treats type 2 diabetes, heart failure, and chronic kidney disease, and without help it's genuinely expensive — brand-name pricing runs anywhere from roughly $550 to $780 for a single 30-day supply. AstraZeneca's savings card can bring that down sharply for some patients, but the terms are more specific than most coupon sites let on, and two changes in 2026 reshuffled the whole picture: the arrival of a real generic, and AstraZeneca winding down free assistance for the brand. This guide walks through exactly who the card helps, who it doesn't, and what actually makes sense for your situation right now.

1. What Is the Farxiga Savings Card?

The Farxiga Savings Card is AstraZeneca's manufacturer copay assistance program for brand-name Farxiga (dapagliflozin) tablets. It works at the pharmacy counter like a copay card, not a printable coupon: your pharmacist applies it to your prescription and it reduces what you owe based on your insurance situation.

Farxiga Savings Card terms, straight from AstraZeneca
SituationWhat You PayCap
Commercially insuredAs low as $0 per 30-day supplyUp to $175 in savings per fill
Uninsured / cash-payPharmacy price minus AstraZeneca's contributionAstraZeneca pays up to the first $150
Medicare or MedicaidNot eligible for this cardDifferent rules apply — see below

Read the cash-pay terms carefully. "Up to $150" is a contribution toward the price, not a $150 total cost. If your pharmacy charges $650 for Farxiga and you're uninsured, the card can knock $150 off — you're still responsible for roughly $500.

2. Big Update: A Generic Farxiga Now Exists

This is the single most important change for anyone researching Farxiga savings in 2026. On April 6–7, 2026, the FDA approved the first generic versions of dapagliflozin, and more than a dozen manufacturers launched immediately once the core patent expired. That's a real, stocked generic — not just an FDA approval sitting on a shelf waiting for patent litigation to clear.

Why it matters for your wallet: Choosing generic dapagliflozin and applying a free discount coupon can save roughly $460 a month compared to unassisted brand pricing, according to pharmacy pricing trackers. For a lot of uninsured patients, that beats what's left over after the brand card's $150 cash-pay contribution.

One important catch: the current generic label covers type 2 diabetes glycemic control and reducing heart failure hospitalization risk in patients with type 2 diabetes plus cardiovascular disease or risk factors. It does not yet carry brand Farxiga's separate chronic kidney disease indication, or the broader heart failure indication for patients without diabetes. If you take Farxiga specifically for CKD or for heart failure and you don't have type 2 diabetes, ask your prescriber before switching — a straight swap may not be appropriate yet.

This is also exactly why AstraZeneca is winding down free Farxiga assistance through AZ&Me — more on that below. For context, Jardiance (empagliflozin), a competing SGLT2 inhibitor, still has no FDA-approved generic as of 2026, which is part of why Farxiga's savings landscape looks so different from its closest rival right now.

3. Is There a Farxiga Coupon or Manufacturer Coupon?

AstraZeneca does not issue a traditional printable manufacturer coupon for Farxiga. When people search for a "Farxiga coupon" or "Farxiga manufacturer coupon," they're almost always describing the same benefit as the Farxiga Savings Card above — it functions like a coupon at checkout, but it's structured as a copay card with the insurance-based terms described in Section 1.

What patients search for vs. what actually exists
Search TermWhat Actually Exists
Farxiga couponFarxiga Savings Card (manufacturer copay program)
Farxiga manufacturer couponSame Farxiga Savings Card — no separate printable coupon
Farxiga copay cardSame program, insurance-based terms
Coupon for Farxiga without insuranceCash-pay version of the same card — up to $150 off, not $150 total
Third-party Farxiga discount cardGoodRx, SingleCare, Inside Rx — can't be combined with the manufacturer card

Bottom line: If a site advertises a printable "Farxiga coupon," it's referring to this same manufacturer program, or to an independent pharmacy discount card that may or may not beat it. Compare both before you commit — see our GoodRx vs. Inside Rx comparison for how those independent cards typically stack up.

4. Farxiga Copay Card: $0 for Commercially Insured

If you have commercial insurance — through an employer or the ACA marketplace — and your plan's copay or coinsurance for Farxiga is higher than you'd like, the savings card applies at the pharmacy and can bring your out-of-pocket cost down to $0 for a 30-day supply, up to a maximum benefit of $175 per fill.

  • Works automatically at most participating pharmacies once registered.
  • Applies per 30-day fill, not as a one-time benefit.
  • Non-transferable and limited to one card per person; can't be combined with any other discount on the same fill.

Copay accumulator programs can undo this. A growing number of insurers use copay accumulator or maximizer programs that apply the manufacturer's payment to your bill but don't count it toward your deductible or out-of-pocket maximum. That means you could face a larger bill later in the year for other medications. Ask your insurer directly: "Does my plan have a copay accumulator or maximizer program for brand-name drugs?"

5. Farxiga Savings Card Without Insurance

Uninsured patients are eligible for the same card, but the math works differently. AstraZeneca contributes up to the first $150 toward your pharmacy's cash price for each monthly prescription, and you pay whatever is left.

What an uninsured patient actually pays
Pharmacy Cash PriceAstraZeneca's ContributionYour Remaining Balance
~$550$150~$400
~$650$150~$500
~$780$150~$630

This is why so many uninsured patients are better off with generic dapagliflozin plus a free discount coupon than with the brand card's cash-pay benefit. Compare both at your specific pharmacy using a tool like our Drug Price Checker before you decide.

6. AZ&Me Is Closing for Farxiga (2026 Update)

AZ&Me is AstraZeneca's separate, income-based patient assistance program that has historically provided free medication to qualifying uninsured patients. As of May 1, 2026, it stopped accepting new patients for Farxiga and Xigduo XR.

  • Currently enrolled patients can keep receiving free Farxiga or Xigduo XR through December 31, 2026.
  • Final day to request a refill under the program is December 15, 2026.
  • AstraZeneca's stated reason: broad generic dapagliflozin availability beginning in April 2026 made continued free brand assistance unnecessary for most patients going forward.
  • Standard AZ&Me income eligibility for primary and specialty medications remains at or below 300% of the Federal Poverty Level.

If you were counting on AZ&Me and haven't applied yet, you're too late for Farxiga specifically. New applications for Farxiga and Xigduo XR are no longer being accepted. If you already need ongoing assistance, ask your prescriber about generic dapagliflozin, check the patient assistance program directory for other manufacturer or nonprofit options, or use NeedyMeds and BenefitsCheckUp to screen for other programs you may qualify for.

7. Farxiga Cost: Brand vs. Card vs. Generic

Approximate monthly cost by path (August 2026)
OptionTypical Monthly CostBest For
Brand Farxiga, no assistance~$550–$780Not recommended if any assistance applies
Brand Farxiga + Savings Card, commercial insurance$0 (up to $175 off)Commercially insured patients
Brand Farxiga + Savings Card, uninsured~$400–$630 (price minus $150)Uninsured patients who need the brand specifically
Generic dapagliflozin + free couponOften well under $150Most uninsured patients whose indication is covered by the generic label
Medicare Part D~$38.82 averageMedicare enrollees, per AstraZeneca's published 2026 average

See our Medicare Part D overview for how formulary tiers and the annual out-of-pocket cap affect what you'll actually pay through a Part D plan, and our Extra Help (LIS) guide if your income is limited and you're on Medicare.

8. Eligibility & Who Qualifies

Eligible

Commercial Insurance

Employer-sponsored or ACA marketplace plans qualify for the $0, $175-cap benefit.

Eligible

Uninsured / Cash-Pay

Qualifies for the cash-pay benefit — AstraZeneca contributes up to $150 per fill.

Not Eligible

Medicare

Excluded from this card. Part D pricing and Extra Help apply instead.

Not Eligible

Medicaid

Excluded from this card. State Medicaid formulary rules apply instead.

9. Income Limits Compared

The Farxiga Savings Card has no income requirement at all — it's based purely on insurance status. AZ&Me, by contrast, is strictly income-based, which is a common point of confusion.

Income limit comparison
ProgramIncome LimitInsurance Requirement
Farxiga Savings CardNoneCommercial insurance or uninsured
AZ&Me (Farxiga, legacy enrollees only)≤300% of Federal Poverty LevelUninsured or Medicare without Extra Help
Medicare Extra Help (LIS)Varies — tied to federal thresholds updated annuallyEnrolled in Medicare Part D

10. Covered Medications Compared

What each program actually covers
ProductSavings CardAZ&MeNotes
Farxiga (dapagliflozin) tabletsYesNew patients: noCore focus of this guide
Xigduo XR (dapagliflozin + metformin)Yes, separate cardNew patients: noSame 2026 phase-out timeline as Farxiga
Generic dapagliflozinNot applicable — brand-only programNot applicableCovered by standard pharmacy discount coupons instead
Jardiance (empagliflozin)Different manufacturer programDifferent manufacturer programNo generic available as of 2026

11. How to Enroll Step-by-Step

1

Confirm your insurance status

Commercial insurance and uninsured cash-pay both qualify for the Farxiga Savings Card; Medicare and Medicaid do not. Know which bucket you're in before you start.

2

Register for the card

Sign up through AstraZeneca's official Farxiga savings page to activate your card, whether you're insured or paying cash.

3

Ask your prescriber about generic dapagliflozin

If your Farxiga prescription is for type 2 diabetes or the covered heart failure indication, ask whether the generic is appropriate — it may be far cheaper than the brand card's remaining balance.

4

Present your card (or a discount coupon) at the pharmacy

Hand over the Farxiga Savings Card for brand-name Farxiga, or a free discount coupon if you and your prescriber have chosen generic dapagliflozin instead.

5

Confirm the price before you pay

Ask the pharmacist to show you the price after the discount is applied. If it doesn't look right, ask them to re-run it as a manufacturer copay card for dapagliflozin.

12. Approval Timelines

What to expect and when
ProgramTypical Timeline
Farxiga Savings Card (commercial)Immediate at pharmacy counter once registered
Farxiga Savings Card (cash-pay)Immediate — no waiting period
AZ&Me (legacy enrollees only)Typically 2–4 weeks for renewals; new Farxiga applications are closed
Prior authorization, if your plan requires itUsually 3–14 business days, longer if appealed

If your Farxiga or generic dapagliflozin prescription is stuck in review, our prior authorization guide covers documentation that typically speeds up approval.

13. Renewal Process

AstraZeneca republishes Farxiga Savings Card terms periodically, generally on a calendar-year cycle. Set a reminder near the start of each year to confirm your card is still active and that the terms — the $175 commercial cap and $150 cash-pay contribution — haven't changed. If your pharmacy suddenly stops applying the discount mid-year, that's usually the first sign a renewal is needed.

AZ&Me enrollees who are grandfathered in for Farxiga should watch two dates closely: December 15, 2026 (final refill request) and December 31, 2026 (full program removal). There is no renewal path after that for Farxiga specifically.

14. Decision Path: Which Option Fits You?

What's your insurance status?
Commercial insurance → the Farxiga Savings Card likely gets you to $0. Go to step 3.
Uninsured / Medicare / Medicaid → the brand card either doesn't apply cleanly or leaves a real balance. Continue.
Is your Farxiga prescribed for type 2 diabetes or the covered heart failure indication?
Yes → ask your prescriber about generic dapagliflozin plus a free discount coupon.
No — it's for CKD or heart failure without diabetes → the generic label may not cover you yet; you likely need the brand.
Are you on Medicare with a limited income?
Yes → check Extra Help (LIS) eligibility before assuming you're stuck at full Part D pricing.
No → compare your Part D plan's formulary tier directly against generic + coupon pricing.
Result: price out your two best options before filling

For most people, this comes down to two real contenders: the brand savings card (best if commercially insured) or generic dapagliflozin with a free coupon (often best if uninsured). Price both at your specific pharmacy before you decide.

15. Real Patient Examples

Commercially insured
Denise, 52 — Type 2 diabetes

Her employer plan puts Farxiga on a high copay tier. Registering for the Farxiga Savings Card brings her cost to $0 per fill, well under the $175 cap.

Uninsured
Marcus, 47 — Between jobs

His pharmacy quotes $620 for brand Farxiga. The cash-pay card knocks off $150, leaving $470. His doctor confirms generic dapagliflozin is appropriate, and with a free coupon he pays a small fraction of that instead.

CKD, no diabetes
Priya, 61 — Chronic kidney disease

She takes Farxiga specifically for CKD and doesn't have type 2 diabetes, so the current generic label doesn't clearly cover her use. She stays on brand Farxiga and uses the Savings Card's commercial-insurance benefit through her plan.

16. Pros and Cons

Pros

  • No income requirement for the Savings Card itself
  • Can reach $0 out-of-pocket for commercially insured patients
  • A real, stocked generic now exists as a lower-cost fallback
  • Instant activation — no application review or waiting period

Cons

  • Cash-pay benefit only offsets $150 — not a flat low price
  • Excludes Medicare and Medicaid entirely
  • AZ&Me is closed to new Farxiga applicants as of May 2026
  • Generic doesn't yet cover the CKD or non-diabetic heart failure indications

17. Common Mistakes

Assuming the uninsured card caps your total cost at $150, instead of just reducing the price by up to $150.

Trying to apply for AZ&Me for Farxiga today — new applications closed on May 1, 2026.

Switching to generic dapagliflozin for CKD or non-diabetic heart failure without checking with your prescriber first.

Trying to use the Farxiga Savings Card while enrolled in Medicare or Medicaid.

Stacking a GoodRx or SingleCare coupon with the manufacturer card on the same fill.

Not asking about a copay accumulator program, which can quietly erase the benefit's effect on your deductible.

Frequently Asked Questions

It's AstraZeneca's manufacturer copay program for Farxiga (dapagliflozin). Eligible commercially insured patients pay as little as $0 for a 30-day supply, subject to a maximum savings of $175 per fill. Cash-paying patients get AstraZeneca contributing up to the first $150 toward the price, with the patient responsible for the remaining balance.

AstraZeneca does not issue a traditional printable manufacturer coupon for Farxiga. The Farxiga Savings Card functions as the manufacturer-backed discount. Eligible commercially insured patients pay as little as $0 per month, subject to a $175 maximum savings per 30-day supply. Cash-paying patients get up to $150 off, not a flat $150 total price.

Not as a new applicant. As of May 1, 2026, AZ&Me stopped accepting new patients for Farxiga and Xigduo XR. Patients already enrolled before that date can keep receiving support through December 31, 2026, with a final refill request deadline of December 15, 2026. AstraZeneca cites broad generic dapagliflozin availability as the reason the program is being phased out.

It's bioequivalent for the indications on its label, but the current generic labeling covers type 2 diabetes glycemic control and reducing heart failure hospitalization risk in patients with type 2 diabetes and cardiovascular disease or risk factors. It does not yet carry brand Farxiga's chronic kidney disease indication or its broader heart failure indication in patients without diabetes, so talk to your prescriber before switching if you take it for either of those reasons.

Brand-name Farxiga typically costs between $550 and $780 for a 30-day supply without insurance or a savings card, depending on the pharmacy. With the manufacturer's cash-pay savings card, AstraZeneca covers up to $150 of that price, leaving a real balance in the hundreds of dollars. Generic dapagliflozin, especially combined with a free discount coupon, is usually far cheaper.

No. The Farxiga Savings Card excludes patients enrolled in any state or federally funded prescription insurance program, including Medicare and Medicaid. Medicare Part D enrollees pay an average of about $38.82 a month for Farxiga under current plan pricing instead, and Medicaid out-of-pocket costs vary by state.

Commercially insured patients can reach $0 out-of-pocket, up to $175 in savings per fill. Cash-pay patients don't get a flat low price — AstraZeneca contributes up to $150 toward whatever the pharmacy charges, and the patient pays whatever is left, which is often several hundred dollars for brand-name Farxiga.

Xigduo XR (dapagliflozin and metformin) has its own related AstraZeneca copay card with similar terms, and it follows the same AZ&Me phase-out timeline as Farxiga. Check AstraZeneca's savings site for the current Xigduo XR-specific card details.

For most uninsured patients, yes. Since the FDA approved the first generic dapagliflozin tablets in April 2026, more than a dozen manufacturers have launched versions, and pairing generic dapagliflozin with a free discount coupon can save around $460 a month compared to unassisted brand pricing — often beating what's left over after the brand card's $150 cash-pay contribution.

Patients with commercial insurance and cash-paying uninsured patients both qualify, with no income requirement. Patients enrolled in Medicare, Medicaid, or other government-funded insurance are not eligible for this specific card.

Ask your prescriber whether generic dapagliflozin is appropriate for your diagnosis, then compare its price with a free discount coupon against your remaining brand-name balance. Patients on Medicare with limited income should also check Extra Help (LIS) eligibility, and NeedyMeds or BenefitsCheckUp can surface other state or nonprofit assistance.

Yes. AstraZeneca republishes program terms periodically, and the card is generally tied to a calendar-year cycle. Reverify your card's current terms and expiration date at least once a year, and immediately if your pharmacy stops applying the discount.

No, pharmacies generally apply only one discount per transaction. Compare the price under the Farxiga Savings Card against a free GoodRx or SingleCare coupon for either brand or generic dapagliflozin, and use whichever comes out lower at your specific pharmacy.

If you're managing more than Farxiga — insulin, a GLP-1, or another chronic prescription — it's worth checking whether the manufacturer behind it runs a similar program. Eli Lilly's assistance runs through Lilly Cares and Novo Nordisk's through NovoCare, and both companies publish their own eligibility rules directly on their sites — see Eli Lilly and Novo Nordisk for the manufacturers themselves. Our manufacturer savings card guides break these down the same way this page breaks down Farxiga.

For anything involving the FDA's generic drug approval process, the FDA's own generic dapagliflozin announcement is the primary source. For Medicare specifics, Medicare.gov and CMS cover Part D formulary rules and the drug price negotiation program that already lowered Farxiga's Medicare pricing in 2026.

Editorial Policy: This guide reflects AstraZeneca's published Farxiga Savings Card terms, AZ&Me's official program update, and the FDA's April 2026 generic dapagliflozin approval as of August 6, 2026. Program eligibility, pricing, and expiration dates are controlled by AstraZeneca and the FDA and are subject to change without notice. This is educational content, not medical or financial advice — talk to your prescriber before switching between brand and generic dapagliflozin.

Evan Brown
About the Author
Evan Brown — Prescription Savings Researcher

Evan Brown is a medical content researcher who specializes in translating manufacturer savings programs and insurance rules into clear, actionable guidance for patients.

View Full Profile →
Dr. Megan Harris, MD
Medical Review
Dr. Megan Harris, MD

Dr. Megan Harris, MD reviews health content for medical accuracy, checking program eligibility and drug information against current manufacturer and FDA guidance.

View Full Profile →

Contact Refill Relay